Industry Program

Friday 23 October 2020
1430-1500	Pre-Congress workshop Biomechanics & Movement Workshop with BJC Health Brought to you by

Saturday 24 October
1130 – 1245	Morning symposium 1 “Beyond remission” based on patients’ subjective experiences for improved RA control	Morning symposium 2	Morning symposium 3 New evidence on the JAK inhibitor and its clinical implications for rheumatoid arthritis
	Brought to you by	Brought to you by	Brought to you by
1315 – 1445	Lunch symposium 1 Prospects for JAK inhibitors in the treatment of rheumatoid arthritis Brought to you by		Lunch symposium 2 Basic and Clinical of Rheumatology Brought to you by
1740 – 1840	Evening symposium 1	Evening symposium 2 Treat-to-target in SLE: addressing short- and long-term treatment goals	Evening symposium 3 ILD in Focus: Time to prioritize the lung in CTDs	Evening symposium 4 Perspectives around the accumulated evidence for IL-6 in autoimmune disease
	Brought to you by	Brought to you by	Brought to you by	Brought to you by

Sunday 25 October
1130 – 1245	Morning symposium 5 Treatment of Rheumatoid Arthritis: Past and Future	Morning symposium 6 To continue, taper or discontinue biologics – Implications on RA treatment outcomes	Morning symposium 7	Morning symposium 8
	Brought to you by	Brought to you by
1315 – 1445	Lunch symposium 3 New insights for clinical practice in Spondyloarthritis, SpA Brought to you by		Lunch symposium 4 New therapeutic alternatives for rheumatic diseases: Individualizing the treatment approach Brought to you by
1740 – 1840	Evening symposium 5 Addressing Unmet Needs in RA and PsA: The Right Drug for the Right Patient	Evening symposium 6 The role of interleukin-6 in rheumatoid arthritis	Evening symposium 7 Denosumab, anti-RANKL antibody, for the treatment of joint destruction in RA. − From DRIVE & DESIRABLE studies	Evening symposium 8
	Brought to you by	Brought to you by	Brought to you by